TRAIL seems to be involved in MI, but its signaling pathway is very complex due to the multiple receptors able to bind it; however, trials demonstrating the safety of molecules affecting TRAIL signaling are ongoing for the treatment of cancer and, in the future, could also be used for MI management. The gene discussed is TNFSF10; the disease is cancer.